Dr. Balakrishna Koneru, an assistant professor of pediatrics at Texas Tech University Health Sciences Center (TTUHSC), is spearheading pioneering research aimed at transforming the clinical landscape of osteosarcoma management. His work recently received significant endorsement via a two-year, $198,822 grant from the Cancer Prevention and Research Institute of Texas (CPRIT), dedicated to fostering original and regional cancer research, particularly in historically underserved areas over 100 miles from recognized National Cancer Institute (NCI)-designated centers within Texas.

Dr. Koneru’s investigative project zeroes in on a molecular subtype of osteosarcoma cells distinguished by the activation of an alternative telomere elongation mechanism, termed ALT (Alternative Lengthening of Telomeres). Telomeres, protective caps at chromosome termini, progressively shorten during normal cellular division, ultimately triggering senescence. Cancer cells evade this limitation primarily by reactivating telomerase, an enzyme that replenishes telomere length, thereby enabling unchecked proliferation. However, a subset of cancers, including a significant fraction of osteosarcomas, exploit a telomerase-independent pathway via ALT, a homologous recombination-based telomere maintenance process that remains poorly understood and therapeutically untargeted.

Recent advances led by Dr. Koneru’s team employed high-throughput CRISPR-Cas9 genomic screening techniques to systematically disrupt numerous genes and elucidate their roles in sustaining the viability of ALT-positive osteosarcoma cells. This comprehensive functional genomics approach identified Integrin Subunit Alpha V (ITGAV) as a critical molecular player indispensable for the survival of these tumors. The ITGAV protein is a transmembrane receptor involved in cell adhesion, migration, and intracellular signaling cascades, functions that are often hijacked by malignant cells for metastatic progression and resistance to apoptosis.

The grant-funded research aims to mechanistically characterize the dependency of ALT-driven osteosarcomas on ITGAV. Experimental strategies will encompass targeted gene editing, in vitro tumor cell viability assays, and in vivo modeling to delineate the impact of ITGAV disruption on tumor growth dynamics. By elucidating the downstream signaling pathways modulated by ITGAV, the study aspires to reveal vulnerabilities that could be exploited to design targeted therapeutics.

An outstanding facet of this investigation is its potential for clinical translation. Should ITGAV prove to be an effective therapeutic target, pharmaceutical development efforts could be directed toward small molecule inhibitors or monoclonal antibodies specifically intercepting ITGAV function. Such interventions could represent the first tailored treatment option for ALT-dependent osteosarcoma patients, who currently have limited alternatives beyond surgery and conventional chemotherapy.

Moreover, the implications of this work may extend beyond osteosarcoma. Several other sarcomas and aggressive pediatric cancers, including certain neuroblastomas, exhibit high prevalence of the ALT phenotype. Thus, therapeutic strategies derived from understanding ITGAV’s role could have broader oncological relevance, paving the way for novel treatments for a range of hard-to-treat malignancies characterized by ALT-based telomere maintenance.

Dr. Koneru emphasizes the novelty and critical nature of this research, which resides at the intersection of cancer biology, molecular genetics, and translational medicine. The integration of cutting-edge CRISPR technology with a focused inquiry into telomere biology exemplifies the innovative approaches needed to tackle cancers that have eluded standard treatment for decades.

The CPRIT Texas Regional Excellence in Cancer Pilot Study Award facilitates this exploratory research by providing resources to amplify Dr. Koneru’s preliminary findings concerning ITGAV’s indispensability in ALT-positive osteosarcomas. This support is instrumental in enabling detailed mechanistic studies and validation necessary to substantiate ITGAV as a viable drug target.

Ultimately, the success of this initiative could transform the therapeutic paradigm for pediatric and young adult osteosarcoma patients, transforming a fatal diagnosis into a manageable or potentially curable disease. By addressing an understudied and molecularly distinct subclass of osteosarcoma, Dr. Koneru’s research opens new vistas in personalized oncology and targeted drug development.

This endeavor exemplifies the importance of regional cancer research initiatives in bridging gaps in cancer treatment innovation, particularly for underserved populations distant from major cancer centers. The findings from this work not only promise advances in cancer therapeutics but also reinforce the value of strategic funding to propel novel scientific exploration in neglected domains.

The future trajectory includes not only expanding the understanding of ITGAV’s mechanistic role in ALT maintenance but also facilitating preclinical studies that could eventually culminate in clinical trials. As the oncology community continues to unravel the complexity of tumor biology, targeted interventions such as those proposed by Dr. Koneru stand at the forefront of personalized medicine for aggressive childhood cancers.

Subject of Research: Osteosarcoma, Alternative Lengthening of Telomeres (ALT), Integrin Alpha V (ITGAV), Targeted Cancer Therapy

Article Title: Investigating Integrin Subunit Alpha-V as a Therapeutic Target in ALT-Dependent Osteosarcomas

News Publication Date: Not Provided

Web References: Not Provided

References: Not Provided

Image Credits: TTUHSC

Keywords: Biomedical engineering, Clinical medicine, Diseases and disorders, Epidemiology, Health care, Human health, Medical specialties, Pharmaceuticals, Pharmacology

Diffuse intrinsic pontine glioma, particularly the IDH wild-type variant common in children, is characterized by its highly infiltrative growth within the brainstem—a region critical for basic life functions and therefore a notoriously inhospitable target for surgery and radiation. The inability to safely remove or effectively irradiate these tumors has driven researchers to develop alternative therapeutic platforms, with oncolytic virotherapy emerging as a compelling contender due to its unique mechanism of selectively infecting and destroying cancer cells while sparing healthy tissue.

The Ad-TD-nsIL12 virus represents a sophisticated fusion of genetic engineering and immunotherapeutic strategy. This oncolytic adenovirus is designed to preferentially replicate within tumor cells and concurrently express a novel form of the cytokine interleukin-12 (IL-12) fused with a nanobody, enhancing its stability and localized immune modulation. IL-12 acts as a potent immunostimulant, promoting the activation of cytotoxic T lymphocytes and natural killer cells that can target and eradicate cancer cells, while the viral infection induces direct oncolysis, effectively a double-pronged assault.

In the two phase I clinical trials, which enrolled children diagnosed either with primary or progressive IDH wild-type DIPG, investigators sought to establish safety profiles, dosing parameters, and preliminary efficacy signals for Ad-TD-nsIL12. Despite the inherent challenges of delivering therapeutics across the blood-brain barrier and into the pons—a densely packed and critical brainstem structure—the trials successfully administered the virus via localized intratumoral or intracerebral infusions with manageable adverse effects.

The clinical data reveal that Ad-TD-nsIL12 was well tolerated among pediatric participants, with no unexpected serious adverse events related to the therapy. Importantly, biomarker analyses indicated a robust induction of immune responses within the tumor microenvironment, marked by infiltration of activated T cells and increased cytokine production in situ. These immunological changes correlated with radiographic evidence of tumor stabilization or regression in a subset of patients, suggesting that the dual mechanism of viral oncolysis and immunostimulation is operational and therapeutically relevant.

From a mechanistic perspective, the study underscores the critical role of the tumor immune microenvironment in mediating response to virotherapy. The enhanced expression of IL-12 by Ad-TD-nsIL12 appears to recalibrate the immunosuppressive milieu characteristic of DIPG into a more immunogenic landscape. This shift potentiates endogenous immune effectors capable not only of direct cytotoxicity but also of generating immunological memory, which may translate to durable tumor control and reduced relapse risk.

The engineering of the nanobody-fused IL-12 addresses a pivotal limitation of cytokine therapies—the risk of systemic toxicity due to widespread cytokine diffusion. By tethering the cytokine payload to a viral backbone that restricts expression predominantly to infected tumor cells, the approach achieves high local cytokine concentration with minimal systemic exposure. This targeted immunomodulation is a major innovation, increasing the therapeutic index and potentially enabling combination with other immunotherapeutic agents or standard treatments.

These pioneering trials also refined methods for administering the virus safely within the delicate pontine region. Utilizing advanced stereotactic neurosurgical techniques and real-time imaging guidance, researchers could navigate the complexity of the brainstem’s anatomy, enabling precise viral delivery while minimizing procedural risks. This technical achievement is a critical enabler for translating oncolytic virotherapy into routine clinical practice for DIPG.

Though the study population was limited and the trials primarily focused on safety and feasibility endpoints, the observed trends toward clinical benefit are encouraging, warranting further investigation in expanded trials with larger cohorts and extended follow-up. Future studies will aim to optimize viral dosing, explore biomarkers predictive of response, and evaluate the virus in combination with checkpoint inhibitors, radiation, or chemotherapy to amplify therapeutic effects.

The implications of this research extend beyond DIPG to other recalcitrant brain tumors and cancers where locally confined viral immunotherapies may overcome the limitations of systemic treatments. The modular design of Ad-TD-nsIL12 allows for tailoring to different tumor types or incorporation of alternative immunomodulatory payloads, heralding a new generation of precision viral therapies that can be customized for individual tumor immunobiologies.

Moreover, this work exemplifies the power of translational collaboration between virologists, immunologists, neurosurgeons, oncologists, and bioengineers. The convergence of expertise enabled the rapid bench-to-bedside advancement of a complex biologic therapeutic, emphasizing the necessity of multidisciplinary approaches to tackle formidable cancers like DIPG.

In the context of pediatric oncology, where safe and effective new treatments are desperately needed, the promise shown by Ad-TD-nsIL12 provides cautious optimism. While the road to regulatory approval and widespread clinical application will require rigorous validation in later-phase trials, this study has carved out a critical proof-of-concept for oncolytic immunovirotherapy as a viable strategy in childhood brain tumors.

This research also raises important questions regarding long-term viral persistence, immune-related adverse events, and the potential development of resistance mechanisms. Addressing these aspects will be essential to fully harness the therapeutic potential of Ad-TD-nsIL12 and similar agents.

Nevertheless, the initial clinical experience described here marks a milestone in the fight against DIPG—a notoriously intractable tumor. By harnessing the natural tropism and cytolytic capabilities of adenoviruses, augmented by targeted cytokine delivery, scientists are opening new frontiers in immuno-oncology that may ultimately translate into improved survival and quality of life for affected children and their families.

In conclusion, the trials investigating the oncolytic adenovirus Ad-TD-nsIL12 represent a significant leap forward in the development of innovative therapies for diffuse intrinsic pontine glioma. The dual-action strategy that combines direct viral-mediated tumor cell destruction with potent immune activation addresses critical challenges in treating this devastating disease, illuminating a path towards more effective and safer interventions in pediatric neuro-oncology.

Subject of Research: Oncolytic adenovirus Ad-TD-nsIL12 in pediatric IDH wild-type diffuse intrinsic pontine glioma (DIPG)

Article Title: The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials

Article References:
Qian, X., Ning, W., Yang, J. et al. The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials. Nat Commun 16, 6934 (2025). https://doi.org/10.1038/s41467-025-62260-5

Image Credits: AI Generated